Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first product on the market.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。